[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574997":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":29,"collaborators":7,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":37,"eligibilityCriteria":38,"healthyVolunteers":33,"sex":39,"minAge":40,"maxAge":7,"enrollmentInfo":41,"targetDuration":7,"studyType":44,"phases":7,"briefSummary":45,"conditions":46,"keywords":7,"overallStatus":55,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Huaxiang wu","CONTACT","+8613757118395","wuhx8855@sina.com",[15],{"facility":16,"status":7,"city":17,"state":7,"zip":7,"country":18,"countryCode":19,"cosmosGeoPoint":20,"geoPoint":25,"contacts":26},"The Second Affiliated Hospital of Zhejiang University","Hangzhou","China","CN",{"type":21,"coordinates":22},"Point",[23,24],120.16142,30.29365,{"lat":24,"lon":23},[27],{"name":28,"role":11,"phone":12,"phoneExt":7,"email":13},"Huaxiang Wu",{"type":30,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100574997","a-registry-study-assessing-pro-dosing-patterns-and-safety-of-vunakizumab-in-patients-with-general-rheumatic-diseases-100574997",false,"NCT06766552","A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.","A Multicenter Registry Study Assessing Patient Reported Outcome, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.","V-MIRACLE","Inclusion Criteria:\n\n1. Diagnosed with rheumatic autoimmune diseases such as ankylosing spondylitis\u002Fradiologically negative axial spondyloarthritis\u002Fpsoriatic arthritis\u002Fpolymyalgia rheumatica\u002FTakayasu arteritis\u002Fgiant cell arteritis\u002F non-ocular Behcet's disease\u002F enthesitis-related arthritis;\n2. Currently receiving or planning to receive fulvezinib treatment;\n3. Can follow up according to the doctor's advice;\n4. Able to understand and sign the informed consent form, understand the purpose of this study, and voluntarily participate in this study.\n\nExclusion Criteria:\n\n1.Investigator believes will prevent the subject from following and completing the study protocol","ALL","18 Years",{"count":42,"type":43},10000,"ESTIMATED","OBSERVATIONAL","Ankylosing spondylitis, radiographically negative axial spondyloarthritis, psoriatic arthritis, polymyalgia rheumatica, Takayasu arteritis, giant cell arteritis, non-ocular Behcet's disease, and enthesitis-related arthritis are common diseases in rheumatology. Traditional anti-rheumatic drugs are less effective and have greater side effects than biological agents. At present, there has been no large-scale registration study on rheumatic autoimmune diseases such as spondyloarthritis in China. However, data such as patient characteristics, medication patterns, and patient outcome reports of different rheumatology diseases can often serve as a reference for rheumatology clinicians to reasonably select treatment methods for different patients. Therefore, a large-scale registration study is needed to fill the gap in multi-disease registration studies in rheumatology departments in China.",[47,48,49,50,51,52,53,54],"Ankylosing Spondylitis (AS)","Psoriatic Arthritis (PsA)","Nr-axSpA","Polymyalgia Rheumatica (PMR)","Takayasu Arteritis (TAK)","Giant Cell Arteritis (GCA)","Behcet's Disease","Enthesitis-related Arthritis","NOT_YET_RECRUITING","2025-01-08",{"date":58,"type":59},"2025-01-09","ACTUAL",{"date":61,"type":43},"2025-01-30",{"date":63,"type":43},"2030-06-30",{"name":5,"class":6},1]